Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
triamcinolone + levobupivacaine is a combination drug therapy consisting of a synthetic corticosteroid and a long-acting local anesthetic. It is being evaluated in clinical trials by the Hospital de Braga for the treatment of quadratus lumborum syndrome, a condition associated with chronic low back pain and myofascial trigger points. Triamcinolone acts as a glucocorticoid receptor agonist, providing potent anti-inflammatory effects that help reduce muscle irritation and pain. Levobupivacaine, the S-enantiomer of bupivacaine, is a voltage-gated sodium channel blocker that provides regional anesthesia by inhibiting nerve impulse conduction. The combination is typically administered via ultrasound-guided infiltration into the quadratus lumborum muscle to achieve both immediate analgesic and sustained anti-inflammatory benefits.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on triamcinolone + levobupivacaine.